Deep learning-based diagnosis from endobronchial ultrasonography images of pulmonary lesions
- PMID: 35962181
- PMCID: PMC9374687
- DOI: 10.1038/s41598-022-17976-5
Deep learning-based diagnosis from endobronchial ultrasonography images of pulmonary lesions
Abstract
Endobronchial ultrasonography with a guide sheath (EBUS-GS) improves the accuracy of bronchoscopy. The possibility of differentiating benign from malignant lesions based on EBUS findings may be useful in making the correct diagnosis. The convolutional neural network (CNN) model investigated whether benign or malignant (lung cancer) lesions could be predicted based on EBUS findings. This was an observational, single-center cohort study. Using medical records, patients were divided into benign and malignant groups. We acquired EBUS data for 213 participants. A total of 2,421,360 images were extracted from the learning dataset. We trained and externally validated a CNN algorithm to predict benign or malignant lung lesions. Test was performed using 26,674 images. The dataset was interpreted by four bronchoscopists. The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the CNN model for distinguishing benign and malignant lesions were 83.4%, 95.3%, 53.6%, 83.8%, and 82.0%, respectively. For the four bronchoscopists, the accuracy rate was 68.4%, sensitivity was 80%, specificity was 39.6%, PPV was 76.8%, and NPV was 44.2%. The developed EBUS-computer-aided diagnosis system is expected to read EBUS findings that are difficult for clinicians to judge with precision and help differentiate between benign lesions and lung cancers.
© 2022. The Author(s).
Conflict of interest statement
NK has received personal fees from Olympus Medical Systems Corporation outside the work performed. YT reports personal fees from AstraZeneca, Daiichi Sankyo Co., Ltd., Pfizer Health Research Foundation, and Chugai Pharmaceutical Co., Ltd., outside the work performed. TI has received personal fees from Boehringer-Ingelheim, AstraZeneca, Daiichi Sankyo Co. Ltd, Pearl Therapeutics Inc., Janssen Pharmaceutical K.K., and Pfizer outside the work performed. TH, YS, YA, MH, and AT have no conflicts of interest to declare. We built a CNN-CAD system in partnership with Olympus Medical Systems Corporation. However, there is no economic benefit to Olympus Medical Systems Corporation in this study. This work was supported by JSPS KAKENHI Grant Number JP22K18185.
Figures
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
